Understand the source comparison
AD Model Selection: Genetic vs Pharmacological
AD research model selection is critical: different models recapitulate different pathological features with varying fidelity. 5xFAD mice develop aggressive amyloid pathology from 2 months with cognitive deficits from 4 months — useful for rapid intervention st
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- AD research model selection is critical: different models recapitulate different pathological features with varying fidelity. 5xFAD mice develop aggressive amyloid pathology from 2 months with cognitive deficits from 4 months — useful for rapid intervention studies targeting Aβ and downstream synaptic effects but lacking significant tau tangles. 3xTg-AD mice develop both Aβ plaques and tau pathology from 6 months — essential for tau research questions (MOTS-C, GHK-Cu AT8 endpoints) but at the cost of slower phenotype development. APPswe/PS1ΔE9 (also called APP/PS1) develop plaques from 6-8 months with moderate cognitive decline — more tractable for prevention/early intervention research (Epitalon). Pharmacological models (scopolamine cholinergic block, intrahippocampal Aβ injection) provide acute, reversible disruption useful for mechanistic pharmacological studies but lack the progressive pathology of transgenic models.
- For peptide research, the choice should match the mechanism under study: Semax cholinergic rescue → 5xFAD or scopolamine; GHK-Cu oxidative/synaptic → 5xFAD intervention; MOTS-C mitochondrial/tau → 3xTg-AD; Epitalon circadian/prevention → APP/PS1 early intervention; Selank neuroinflammation/LTP → 5xFAD.